Biofrontera (NASDAQ:BFRI) Earns “Buy” Rating from Benchmark

Benchmark reissued their buy rating on shares of Biofrontera (NASDAQ:BFRI) in a report released on Friday morning,Benzinga reports. Benchmark currently has a $7.00 target price on the stock.

Biofrontera Stock Down 8.4 %

NASDAQ:BFRI opened at $0.67 on Friday. Biofrontera has a 12-month low of $0.61 and a 12-month high of $4.04. The stock’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.08. The firm has a market capitalization of $3.72 million, a P/E ratio of -0.30 and a beta of 0.50.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.